CCA
GILD icon

Criterion Capital Advisors’s Gilead Sciences GILD Stock Holding History

Criterion Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$5.21K Hold
76
– – ﹤0.01% 287
2024
Q3 		$5.21K Hold
76
– – ﹤0.01% 287
2024
Q2 		$5.21K Hold
76
– – ﹤0.01% 287
2024
Q1 		$5.57K Hold
76
– – ﹤0.01% 281
2023
Q4 		$6.16K Buy
+76
New +$5.91K ﹤0.01% 287

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Criterion Capital Advisors's GILD Position: Q4 2024 in Review

Criterion Capital Advisors held its Gilead Sciences (GILD) position steady in Q4 2024 at 76 shares worth $5.21K. The position accounts for ﹤0.01% of the portfolio, ranked #287.

Criterion Capital Advisors first reported a position in GILD in Q4 2023 and has held it in 5 quarters since. The position peaked at $6.16K in Q4 2023. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

  • Criterion Capital Advisors held 76 shares of Gilead Sciences worth $5.21K as of Q4 2024.
  • Criterion Capital Advisors left its Gilead Sciences share count unchanged in Q4 2024.
  • Gilead Sciences made up ﹤0.01% of Criterion Capital Advisors's portfolio in Q4 2024, its #287 holding.
  • Criterion Capital Advisors first reported a position in Gilead Sciences in Q4 2023 and has held it in 5 quarters since.
  • Criterion Capital Advisors's Gilead Sciences position peaked at $6.16K in Q4 2023.
  • 1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on Criterion Capital Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.